Surfing the NASH Tsunami

What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25

September 09, 2020 HEP Dynamics LLC Season 1 Episode 25
Surfing the NASH Tsunami
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
Chapters
Surfing the NASH Tsunami
What Exactly Are We Trying To Achieve In Early-Stage NASH Therapy? Ep 25
Sep 09, 2020 Season 1 Episode 25
HEP Dynamics LLC

The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.

The Surfers considered the implication of a Digital ILC presentation by James Paik et al. titled "Causes of death in patients with non-alcoholic fatty liver disease (NAFLD): data from national vital statistics system (NVSS)." The presentation demonstrated that liver disease, not cardiovascular, is the leading cause of death for NAFLD patients, with broad implications for treating early-stage patients. Surfers asked: If NAFLD patients "feel bad" all the time, can patient-reported outcomes become a primary measure? Shouldn't metabolic measures remain vitally important for patients most of whom are obese and exhibit concomitant Type 2 diabetes or cardiovascular disease? And which test(s) provide the greatest support for FibroScan in demonstrating positive predictive value? A tremendous amount of content and tips from Dr. Harrison and Prof. Schattenberg. You'll want to listen more than once!

Show Notes

The Surfers and guest Joern Schattenberg consider the implications of a Digital ILC presentation stating that the liver, not cardiovascular disease, is the leading cause of death for NAFLD patients.

The Surfers considered the implication of a Digital ILC presentation by James Paik et al. titled "Causes of death in patients with non-alcoholic fatty liver disease (NAFLD): data from national vital statistics system (NVSS)." The presentation demonstrated that liver disease, not cardiovascular, is the leading cause of death for NAFLD patients, with broad implications for treating early-stage patients. Surfers asked: If NAFLD patients "feel bad" all the time, can patient-reported outcomes become a primary measure? Shouldn't metabolic measures remain vitally important for patients most of whom are obese and exhibit concomitant Type 2 diabetes or cardiovascular disease? And which test(s) provide the greatest support for FibroScan in demonstrating positive predictive value? A tremendous amount of content and tips from Dr. Harrison and Prof. Schattenberg. You'll want to listen more than once!